메뉴 건너뛰기




Volumn 27, Issue 6, 2009, Pages 926-934

High rates of stopping or switching biological medications in veterans with rheumatoid arthritis

Author keywords

Adverse events; Anti TNF medication; Biologic therapy; Registries; Rheumatoid arthritis

Indexed keywords

ABATACEPT; ADALIMUMAB; ETANERCEPT; INFLIXIMAB; METHOTREXATE; PREDNISONE; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; RITUXIMAB;

EID: 76649126207     PISSN: 0392856X     EISSN: 1593098X     Source Type: Journal    
DOI: None     Document Type: Article
Times cited : (26)

References (39)
  • 1
    • 20244372077 scopus 로고    scopus 로고
    • Therapeutic strategies for rheumatoid arthritis
    • O'DELL JR: Therapeutic strategies for rheumatoid arthritis. N Engl J Med 2004; 350: 2591-602.
    • (2004) N Engl J Med , vol.350 , pp. 2591-2602
    • O'DELL, J.R.1
  • 2
    • 35448956495 scopus 로고    scopus 로고
    • Rheumatoid arthritis: Diagnosis and management
    • MAJITHIA V, GERACI SA: Rheumatoid arthritis: diagnosis and management. Am J Med 2006; 120: 936-9.
    • (2006) Am J Med , vol.120 , pp. 936-939
    • MAJITHIA, V.1    GERACI, S.A.2
  • 3
    • 0035056003 scopus 로고    scopus 로고
    • Anti-TNF-α therapy of rheumatoid arthritis: What have we learned?
    • FELDMANN M, MAINI RN: Anti-TNF-α therapy of rheumatoid arthritis: What have we learned? Annu Rev Immunol 2001; 19:163-96.
    • (2001) Annu Rev Immunol , vol.19 , pp. 163-196
    • FELDMANN, M.1    MAINI, R.N.2
  • 4
    • 33947588655 scopus 로고    scopus 로고
    • Switching to etanercept in patients with rheumatoid arthritis with no response to infliximab
    • POI D, PERIN A, MORASSI MP: Switching to etanercept in patients with rheumatoid arthritis with no response to infliximab. Clin Exp Rheumatol 2007; 1: 85-7.
    • (2007) Clin Exp Rheumatol , vol.1 , pp. 85-87
    • POI, D.1    PERIN, A.2    MORASSI, M.P.3
  • 5
    • 14844345548 scopus 로고    scopus 로고
    • Anakinra: Review of recombinant human interleukin-1 receptor antagonist in the treatment of rheumatoid arthritis
    • FURST D: Anakinra: review of recombinant human interleukin-1 receptor antagonist in the treatment of rheumatoid arthritis. Clin Ther 2004; 26: 1960-75.
    • (2004) Clin Ther , vol.26 , pp. 1960-1975
    • FURST, D.1
  • 6
    • 33746961890 scopus 로고    scopus 로고
    • Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: Results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks
    • COHEN SB, EMERY P, GREENWALD MW et al.: Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks. Arthritis Rheum 2006; 54: 2793-806.
    • (2006) Arthritis Rheum , vol.54 , pp. 2793-2806
    • COHEN, S.B.1    EMERY, P.2    GREENWALD, M.W.3
  • 7
    • 47949111861 scopus 로고    scopus 로고
    • Abatacept inhibits structural damage progression in rheumatoid arthritis: Results from the long-term extension of the AIM trial
    • GENANT HK PETERFY CG, WESTHOVENS R et al.: Abatacept inhibits structural damage progression in rheumatoid arthritis: results from the long-term extension of the AIM trial. Ann Rheum Dis 2008; 67: 1084-9.
    • (2008) Ann Rheum Dis , vol.67 , pp. 1084-1089
    • GENANT, H.K.1    PETERFY, C.G.2    WESTHOVENS, R.3
  • 8
    • 33846090262 scopus 로고    scopus 로고
    • Retention rates of tumor necrosis factor blockers in daily practice in 770 Rheumatic Patients
    • DUCLOS M, GOSSEC L, RUYESSEN-WITRAND A et al.: Retention rates of tumor necrosis factor blockers in daily practice in 770 Rheumatic Patients. J Rheumatol 2006; 33: 2433-9.
    • (2006) J Rheumatol , vol.33 , pp. 2433-2439
    • DUCLOS, M.1    GOSSEC, L.2    RUYESSEN-WITRAND, A.3
  • 9
    • 34347225530 scopus 로고    scopus 로고
    • Open label, pilot protocol of patients with rheumatoid arthritis who switch to infliximab after an incomplete response to etanercept: The opposite study
    • FURST D, GAYLIS N, BRAY V et al.: Open label, pilot protocol of patients with rheumatoid arthritis who switch to infliximab after an incomplete response to etanercept: the opposite study. Ann Rheum Dis 2007; 66: 893-9.
    • (2007) Ann Rheum Dis , vol.66 , pp. 893-899
    • FURST, D.1    GAYLIS, N.2    BRAY, V.3
  • 10
    • 34247611914 scopus 로고    scopus 로고
    • Therapy of patients with rheumatoid arthritis: Outcome of infliximab failures switched to etanercept
    • BUCH MH, BINGHAM SJ, BEJARANO V et al.: Therapy of patients with rheumatoid arthritis: outcome of infliximab failures switched to etanercept. Arthritis Rheum 2007; 57: 448-53.
    • (2007) Arthritis Rheum , vol.57 , pp. 448-453
    • BUCH, M.H.1    BINGHAM, S.J.2    BEJARANO, V.3
  • 11
    • 33846875483 scopus 로고    scopus 로고
    • Etanercept maintains the clinical benefit achieved by infliximab in patients with rheumatoid arthritis who discontinued infliximab because of side effects
    • IANNONE F, TROTTA F, MONTECCUCO C et al.: Etanercept maintains the clinical benefit achieved by infliximab in patients with rheumatoid arthritis who discontinued infliximab because of side effects. Ann Rheum Dis 2007; 66: 249-52.
    • (2007) Ann Rheum Dis , vol.66 , pp. 249-252
    • IANNONE, F.1    TROTTA, F.2    MONTECCUCO, C.3
  • 12
    • 33846239331 scopus 로고    scopus 로고
    • Outcomes after switching from one anti-tumor necrosis factor alpha agent in patients with rheumatoid arthritis: Results from a large UK national cohort study
    • HYRICH K, LUNT M, WATSON KD et al.: Outcomes after switching from one anti-tumor necrosis factor alpha agent in patients with rheumatoid arthritis: Results from a large UK national cohort study. Arthritis Rheum 2007; 56: 13-20.
    • (2007) Arthritis Rheum , vol.56 , pp. 13-20
    • HYRICH, K.1    LUNT, M.2    WATSON, K.D.3
  • 13
    • 70350605186 scopus 로고    scopus 로고
    • Switching TNF antagonists in patients with chronic arthritis: An observational study of 488 patients over a four-year period Arthritis Res
    • GOMEZ-REINO JJ, CARMONA L et al.: Switching TNF antagonists in patients with chronic arthritis: an observational study of 488 patients over a four-year period Arthritis Res Ther 2006; 8: R29 1-7.
    • (2006) Ther , vol.8 , Issue.R29 , pp. 1-7
    • GOMEZ-REINO, J.J.1    CARMONA, L.2
  • 14
    • 0345490890 scopus 로고    scopus 로고
    • Treatment with infliximab (Remicade) when etanercept (Enbrel) has failed or vice versa: Data from the STURE registry showing that switching tumour necrosis factor alpha blockers can make sense
    • VAN VOLLENHOVEN R, HARJU A, BRANNEMAR S et al.: Treatment with infliximab (Remicade) when etanercept (Enbrel) has failed or vice versa: data from the STURE registry showing that switching tumour necrosis factor alpha blockers can make sense. Ann Rheum Dis 2003; 62: 1195-8.
    • (2003) Ann Rheum Dis , vol.62 , pp. 1195-1198
    • VAN VOLLENHOVEN, R.1    HARJU, A.2    BRANNEMAR, S.3
  • 15
    • 38149024108 scopus 로고    scopus 로고
    • Rituximab therapy in rheumatoid arthritis in daily practice
    • ASSOUS N, GOSSEC L, DIEUDE P et al.: Rituximab therapy in rheumatoid arthritis in daily practice. J Rheumatol 2008; 35: 31-4.
    • (2008) J Rheumatol , vol.35 , pp. 31-34
    • ASSOUS, N.1    GOSSEC, L.2    DIEUDE, P.3
  • 16
    • 41349091216 scopus 로고    scopus 로고
    • Cardiovascular outcomes in male veterans with rheumatoid arthritis
    • BANERJEE S, COMPTON AP, HOOKER RS et al.: Cardiovascular outcomes in male veterans with rheumatoid arthritis Am J Cardiol 2008; 101: 1201-5.
    • (2008) Am J Cardiol , vol.101 , pp. 1201-1205
    • BANERJEE, S.1    COMPTON, A.P.2    HOOKER, R.S.3
  • 17
    • 0023945481 scopus 로고
    • The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis
    • ARNETT, FC, EDWORTHY SM et al.: The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988; 31: 315-24.
    • (1988) Arthritis Rheum , vol.31 , pp. 315-324
    • ARNETT, F.C.1    EDWORTHY, S.M.2
  • 18
    • 0031715621 scopus 로고    scopus 로고
    • Validation of rheumatoid arthritis improvement criteria that include simplified joint counts
    • VAN GESTEL, AM, HAAGSMA CJ et al.: Validation of rheumatoid arthritis improvement criteria that include simplified joint counts. Arthritis Rheum 1998; 41: 1845-50.
    • (1998) Arthritis Rheum , vol.41 , pp. 1845-1850
    • VAN GESTEL, A.M.1    HAAGSMA, C.J.2
  • 19
    • 43049162899 scopus 로고    scopus 로고
    • Treatment response to a second or third TNF-inhibitor in RA: Results from the South Swedish Arthritis Treatment Group Register
    • KARLSON JA, KRISTEN LE, KAPETANOVIC MC et al.: Treatment response to a second or third TNF-inhibitor in RA: results from the South Swedish Arthritis Treatment Group Register. Rheumatology 2008; 47: 507-13.
    • (2008) Rheumatology , vol.47 , pp. 507-513
    • KARLSON, J.A.1    KRISTEN, L.E.2    KAPETANOVIC, M.C.3
  • 20
    • 29944442627 scopus 로고    scopus 로고
    • The efficiency of switching from infliximab to etanercept and vice-versa in patients with rheumatoid arthritis
    • COHEN G, COURVOISIER N, COHEN JD et al.: The efficiency of switching from infliximab to etanercept and vice-versa in patients with rheumatoid arthritis. Clin Exp Rheumatol 2005; 23: 795-800.
    • (2005) Clin Exp Rheumatol , vol.23 , pp. 795-800
    • COHEN, G.1    COURVOISIER, N.2    COHEN, J.D.3
  • 21
    • 32144446399 scopus 로고    scopus 로고
    • BATHON JM, FLEISCHMANN RM, VAN DER HEIJDE DM et al.: Safety and efficacy of etanercept treatment in elderly subjects with rheumatoid arthritis. J Rheumatol 2006; 33: 234-43.
    • BATHON JM, FLEISCHMANN RM, VAN DER HEIJDE DM et al.: Safety and efficacy of etanercept treatment in elderly subjects with rheumatoid arthritis. J Rheumatol 2006; 33: 234-43.
  • 22
    • 33144490233 scopus 로고    scopus 로고
    • Long term safety of etanercept in elderly subjects with rheumatic diseases
    • FLEISCHMANN R, BAUMGARTNER SW, WEISMAN MH et al.: Long term safety of etanercept in elderly subjects with rheumatic diseases. Ann Rheum Dis 2006; 65: 379-84.
    • (2006) Ann Rheum Dis , vol.65 , pp. 379-384
    • FLEISCHMANN, R.1    BAUMGARTNER, S.W.2    WEISMAN, M.H.3
  • 23
    • 47949106400 scopus 로고    scopus 로고
    • Efficacy and safety of abatacept or infliximab versus placebo in ATTEST: A phase III, multicenter, randomized, double-blind, placebo-controlled study in patients with rheumatoid arthritis and an inadequate response to methotrexate
    • SCHIFF M, KEISERMAN M, CODDING C et al.: Efficacy and safety of abatacept or infliximab versus placebo in ATTEST: a phase III, multicenter, randomized, double-blind, placebo-controlled study in patients with rheumatoid arthritis and an inadequate response to methotrexate. Ann Rheum Dis 2008; 67: 1096-103.
    • (2008) Ann Rheum Dis , vol.67 , pp. 1096-1103
    • SCHIFF, M.1    KEISERMAN, M.2    CODDING, C.3
  • 24
    • 0034735842 scopus 로고    scopus 로고
    • LIPSKY PE, DESIREE MM, VAN DER HEIDJE MD et al.: Infliximab and methotrexate in the treatment of rheumatoid arthritis. N Engl J Med 2000; 343: 22.
    • LIPSKY PE, DESIREE MM, VAN DER HEIDJE MD et al.: Infliximab and methotrexate in the treatment of rheumatoid arthritis. N Engl J Med 2000; 343: 22.
  • 25
    • 38749119069 scopus 로고    scopus 로고
    • Postmarketing surveillance of the safety profile of infliximab in 5000 Japanese patients with rheumatoid arthritis
    • TAKEUCHI T, TATSUKI Y, NOGAMI Y et al.: Postmarketing surveillance of the safety profile of infliximab in 5000 Japanese patients with rheumatoid arthritis. Ann Rheum Dis 2008; 67: 189-94.
    • (2008) Ann Rheum Dis , vol.67 , pp. 189-194
    • TAKEUCHI, T.1    TATSUKI, Y.2    NOGAMI, Y.3
  • 26
    • 38749088727 scopus 로고    scopus 로고
    • The safety and efficacy of adding etanercept to methotrexate or methotrexate to etanercept in moderately active rheumatoid arthritis patients previously treated with monotherapy
    • VAN DER HEIJDJE D, BURMESTER G, MELOGOMES J et al.: The safety and efficacy of adding etanercept to methotrexate or methotrexate to etanercept in moderately active rheumatoid arthritis patients previously treated with monotherapy. Ann Rheum Dis 2008; 67: 182-8.
    • (2008) Ann Rheum Dis , vol.67 , pp. 182-188
    • VAN DER HEIJDJE, D.1    BURMESTER, G.2    MELOGOMES, J.3
  • 27
    • 34447521875 scopus 로고    scopus 로고
    • Anti-tumor necrosis factor a therapy and the risk of serious bacterial infections in elderly patients with rheumatoid arthritis
    • SCHNEEWEISS S, SETOGUCHI S, WEINBLATT ME et al.: Anti-tumor necrosis factor a therapy and the risk of serious bacterial infections in elderly patients with rheumatoid arthritis. Arthritis Rheum 2007; 56: 1754-64.
    • (2007) Arthritis Rheum , vol.56 , pp. 1754-1764
    • SCHNEEWEISS, S.1    SETOGUCHI, S.2    WEINBLATT, M.E.3
  • 28
    • 33646696885 scopus 로고    scopus 로고
    • Anti-TNF therapy in rheumatoid arthritis and risk of serious infections and malignancies
    • BONGARTZ T, SUTTON AJ, SWEETING, MJ et al.: Anti-TNF therapy in rheumatoid arthritis and risk of serious infections and malignancies. JAMA 2006; 295: 2475-82.
    • (2006) JAMA , vol.295 , pp. 2475-2482
    • BONGARTZ, T.1    SUTTON, A.J.2    SWEETING, M.J.3
  • 29
    • 22244443784 scopus 로고    scopus 로고
    • Treatment with tumor necrosis factor blockers is associated with lower incidence of first cardiovascular events in patients with rheumatoid arthritis
    • JACOBSSON LTH, TURRESON C, GULFE A et al.: Treatment with tumor necrosis factor blockers is associated with lower incidence of first cardiovascular events in patients with rheumatoid arthritis. J Rheumatol 2005: 32: 1213-8.
    • (2005) J Rheumatol , vol.32 , pp. 1213-1218
    • JACOBSSON, L.T.H.1    TURRESON, C.2    GULFE, A.3
  • 30
  • 31
    • 47849128962 scopus 로고    scopus 로고
    • Tumor necrosis factor-alpha antagonist use and heart failure in elderly patients with rheumatoid arthritis
    • SETOGUCHI S, SCHNEEWEISS S, AVORN J et al.: Tumor necrosis factor-alpha antagonist use and heart failure in elderly patients with rheumatoid arthritis. Am Heart J 2008; 156: 336-41.
    • (2008) Am Heart J , vol.156 , pp. 336-341
    • SETOGUCHI, S.1    SCHNEEWEISS, S.2    AVORN, J.3
  • 32
    • 36448971598 scopus 로고    scopus 로고
    • Mortality rate in veterans with multiple chronic conditions
    • LEE T, SHIELDS AE, VOGELI C et al.: Mortality rate in veterans with multiple chronic conditions. J Gen Intern Med 2007; 22: 403-7.
    • (2007) J Gen Intern Med , vol.22 , pp. 403-407
    • LEE, T.1    SHIELDS, A.E.2    VOGELI, C.3
  • 33
    • 13444266513 scopus 로고    scopus 로고
    • Increased unrecognized coronary heart disease and sudden deaths in rheumatoid arthritis: A population-based cohort study
    • MARADIT-KREMERS H, CROWSON CS, NICOLA PJ et al.: Increased unrecognized coronary heart disease and sudden deaths in rheumatoid arthritis: a population-based cohort study. Arthritis Rheum 2005; 52: 402-11.
    • (2005) Arthritis Rheum , vol.52 , pp. 402-411
    • MARADIT-KREMERS, H.1    CROWSON, C.S.2    NICOLA, P.J.3
  • 34
    • 34249796662 scopus 로고    scopus 로고
    • Adalimumab alone and in combination with disease-modifying antirheumatic drugs for the treatment for rheumatoid arthritis in clinical practice: The Research in Active Rheumatoid Arthritis (ReAct) trial
    • BURMESTER G, MARIETTE X, MONTECUCCO C et al.: Adalimumab alone and in combination with disease-modifying antirheumatic drugs for the treatment for rheumatoid arthritis in clinical practice: the Research in Active Rheumatoid Arthritis (ReAct) trial. Ann Rheum Dis 2007; 66: 732-9.
    • (2007) Ann Rheum Dis , vol.66 , pp. 732-739
    • BURMESTER, G.1    MARIETTE, X.2    MONTECUCCO, C.3
  • 35
    • 25144513375 scopus 로고    scopus 로고
    • DAS28 best reflects the physician's clinical judgment of response to infliximab therapy in rheumatoid arthritis patients: Validation of the DAS28 score in patients under infliximab treatment
    • CRUYSSEN BV, VAN LOOY S, WYNS B et al.: DAS28 best reflects the physician's clinical judgment of response to infliximab therapy in rheumatoid arthritis patients: validation of the DAS28 score in patients under infliximab treatment. Arthritis Res Ther 2005; 7: R1063-R1071.
    • (2005) Arthritis Res Ther , vol.7
    • CRUYSSEN, B.V.1    VAN, L.S.2    WYNS, B.3
  • 36
    • 27744532112 scopus 로고    scopus 로고
    • Is DAS28 an appropriate tool to assess remission in rheumatoid arthritis?
    • MAKINEN H, KAUTIAINEN H, HANNONEN P et al.: Is DAS28 an appropriate tool to assess remission in rheumatoid arthritis? Ann Rheum Dis 2005; 64: 1410-3.
    • (2005) Ann Rheum Dis , vol.64 , pp. 1410-1413
    • MAKINEN, H.1    KAUTIAINEN, H.2    HANNONEN, P.3
  • 37
    • 35948992182 scopus 로고    scopus 로고
    • Functional health assessment questionnaire (HAQ) and psychological HAQ are associated with and predicted by different factors in rheumatoid arthritis
    • VERSTAPPEN SM, JACOBS JW, HUISMAN AM et al.: Functional health assessment questionnaire (HAQ) and psychological HAQ are associated with and predicted by different factors in rheumatoid arthritis. J Rheumatol 2007; 34: 1837-40.
    • (2007) J Rheumatol , vol.34 , pp. 1837-1840
    • VERSTAPPEN, S.M.1    JACOBS, J.W.2    HUISMAN, A.M.3
  • 38
    • 43049143540 scopus 로고    scopus 로고
    • The relation of hand functions with radiological damage and disease activity in rheumatoid arthritis
    • BIRTANE M, KABAYEL DD, UZUNCA K: The relation of hand functions with radiological damage and disease activity in rheumatoid arthritis Rheumatol Int 2008; 28: 407-12.
    • (2008) Rheumatol Int , vol.28 , pp. 407-412
    • BIRTANE, M.1    KABAYEL, D.D.2    UZUNCA, K.3
  • 39
    • 36849086538 scopus 로고    scopus 로고
    • Effectiveness, predictive response factors, and safety of anti-tumor necrosis factor (TNF) therapies in Anti-TNFNaïve Rheumatoid Arthritis
    • FERNANDEZ-NEBRO A, IRIGOYEN MV, IMMACULADA U et al.: Effectiveness, predictive response factors, and safety of anti-tumor necrosis factor (TNF) therapies in Anti-TNFNaïve Rheumatoid Arthritis. J Rheumatol 2007; 34: 2334-42.
    • (2007) J Rheumatol , vol.34 , pp. 2334-2342
    • FERNANDEZ-NEBRO, A.1    IRIGOYEN, M.V.2    IMMACULADA, U.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.